Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Enzon (ENZN) partner Schering-Plough (SGP) reported results of a 1,219-patient Phase III trial showing that PEG-Intron pegylated interferon alfa-2b, which uses ENZN's polyethylene glycol (PEG) technology,
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury